Intrexon Corp. (XON)

Company Description

Intrexon Corporation, founded in 1998, is a biotechnology company focused on collaborating with companies in Health, Food, Energy, and Environment to create biologically based products that improve quality of life and the health of the planet. At present rates of global industrialization and population growth, food and energy supplies and environmental and healthcare resources are becoming scarcer. We believe Intrexon’s leading Better DNA™ approach to synthetic biology has the potential to provide new, more effective and sustainable solutions to address these challenges.

With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. Working with key collaborators, Intrexon seeks to develop high value applications that can bring better medicines to more people, alleviate shortages of essential nutrients, develop renewable fuels and other resources, and protect the environment..

0374 Seneca Meadows Parkway
Germantown, Maryland 20876
United States



Get BioInvest's perspective on Intrexon's CEO

Latest Company News

Intrexon Corp (XON) Receiving Favorable Media Coverage, Study Finds BNB Daily (blog) - Apr 26, 2017 Intrexon Corp logo Headlines about Intrexon Corp (NYSE:XON) have trended positive on Wednesday, Alpha One Sentiment Analysis reports. Intrexon Corp (XON) Position Lowered by Philadelphia Trust Co. - Sports Perspectives Creative Planning Raises Stake in Intrexon Corp (XON) - BBNS [...]
Wed, Apr 26, 2017 12:33:00 PM, Continue reading at the source
Commit To Purchase Intrexon Corp At $13, Earn 11.9% Using Options Nasdaq - Apr 25, 2017 Investors eyeing a purchase of Intrexon Corp (Symbol: XON) shares, but tentative about paying the going market price of $21.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. [...]
Tue, Apr 25, 2017 4:07:00 PM, Continue reading at the source
Former Pfizer Inc. (NYSE:PFE) Executive Leaves Intrexon Corp (NYSE:XON) Less ... Journal Transcript - Mar 16, 2017 Less than a year after joining Intrexon Corp (NYSE:XON) from Pfizer Inc. (NYSE:PFE), Geno Germano is leaving the company after a reorganization that saw the programs he was heading stripped away and handed to a new entity. [...]
Thu, Mar 16, 2017 5:00:00 AM, Continue reading at the source
Did a Case of Buyer's Remorse Send Intrexon Corporation Down 13% in January? Motley Fool - Feb 6, 2017 Shares of Intrexon (NYSE: XON), a life sciences company focused on the development of proprietary technologies designed to regulate genes with the purpose of treating serious diseases, fell 13% during the month of January, according to data from S&P ... [...]
Mon, Feb 06, 2017 4:41:00 PM, Continue reading at the source
Intrexon to acquire fellow Md. biotech Washington Business Journal - Jan 24, 2017 Germantown-based Intrexon Corp. is swallowing up its fellow Montgomery County biotech, GenVec Inc., a small Gaithersburg gene therapy company that has been struggling to grow since its lead cancer drug candidate failed in late-stage trials in 2010. Intrexon to acquire GenVec in all-stock deal - Seeking Alpha Intrexon to Acquire GenVec to Expand Industry-Leading Gene Delivery Platform - PR Newswire (press release) [...]
Tue, Jan 24, 2017 5:35:00 PM, Continue reading at the source
Courtesy Of Intrexon, A Cautionary Tale For Trusting Investors Seeking Alpha - Dec 23, 2016 Many investors do not need reminding that corporate press releases should always be treated with extreme caution. Those still in doubt should check out an email exchange between the NCI and Intrexon (NYSE:XON) that has just come to light. At issue is a ... [...]
Fri, Dec 23, 2016 7:07:00 PM, Continue reading at the source
Better Buy: Intrexon Corporation vs. bluebird bio Motley Fool - Dec 13, 2016 That's the message engineered biology conglomerate Intrexon (NYSE:XON) is trying to send out to investors. Sure, it has a formidable lineup of clinical trials and biopharma partners, but it's also leveraging the power of biology to develop next ... [...]
Tue, Dec 13, 2016 4:30:00 PM, Continue reading at the source
3 Reasons Intrexon Corp. Stock Could Fall Motley Fool - Nov 23, 2016 Intrexon's (NYSE:XON) sheer number of shots on goal shows tremendous promise for the engineered biology conglomerate. Products in development or nearing commercial launch include everything from genetically engineered mosquitoes for public health ... [...]
Wed, Nov 23, 2016 12:06:00 PM, Continue reading at the source
3 Reasons Intrexon Corp. Stock Could Rise Motley Fool - Nov 15, 2016 Engineered biology conglomerate Intrexon (NYSE:XON) has become a darling stock among biotech investors in the last year. A portfolio of products obtained in numerous acquisitions have either been launched or are nearing commercialization. [...]
Tue, Nov 15, 2016 9:56:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation Motley Fool - Oct 14, 2016 The close relationship between Ziopharm Oncology (NASDAQ:ZIOP) and Intrexon (NYSE:XON) hasn't gone unnoticed by investors -- in fact, it's impossible to overlook since the latter is likely responsible for a majority of the former's $660 million market cap. [...]
Fri, Oct 14, 2016 7:41:00 PM, Continue reading at the source